Equity · Healthcare
ROIV
NASDAQRoivant Sciences (ROIV)
The line runs 35.79 USD on 10 August through 40.82 USD on 11 September, on a scale from 32.5 to 42.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 29.5B USD
- Revenue, year to Mar 2026
- 8.3M USD
- EPS, diluted, year to Mar 2026
- −0.54 USD
- 52-week range
- 12.56 USD – 41.81 USD
- Avg volume
- 632.7K
as of Sep 11, 2026
Have Roivant Sciences (ROIV) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Roivant Sciences insiders reported 15 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 20 Mar 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 3 Nov 2026
Buys 0Sells 15Net sold $74.44MOther filings 35
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | 7.3M USD |
| 28 Oct 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | 7.3M USD |
| 20 Oct 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | 7.0M USD |
| 01 Oct 2026 | Epperly Melissa B,Director | Sell | 17,750 | 641K USD |
| 30 Sep 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | 7.3M USD |
| 15 Sep 2026 | Epperly Melissa B,Director | Sell | 4,938 | 196K USD |
| 15 Sep 2026 | Fitzgerald MeghanDirector | Sell | 5,112 | 203K USD |
| 08 Sep 2026 | Fitzgerald MeghanDirector | Sell | 20,000 | 798K USD |
| 28 Aug 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | 7.2M USD |
| 21 Aug 2026 | Sukhatme MayukhPresident & CIO | Sell | 144,756 | 5.3M USD |
| 20 Aug 2026 | Sukhatme MayukhPresident & CIO | Sell | 17,519 | 653K USD |
| 19 Aug 2026 | Sukhatme MayukhPresident & CIO | Sell | 172,899 | 6.4M USD |
| Sold | 15 open-market sales | 2,047,800 | $74.44M |
Showing the 12 most recent of 15 open-market trades in this window. The figures above count all of them.
35 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 23 Oct 2026 | Epperly Melissa B,Director | Award | 513 | |
| 23 Oct 2026 | Epperly Melissa B,Director | Tax withheld | 116 | 4K USD |
| 23 Oct 2026 | MOMTAZEE JAMES CDirector | Award | 383 | |
| 23 Oct 2026 | MOMTAZEE JAMES CDirector | Tax withheld | 77 | 3K USD |
| 23 Oct 2026 | Oren IlanDirector | Award | 810 | |
| 16 Oct 2026 | Gline MatthewCEO | Tax withheld | 34,638 | 1.2M USD |
| 16 Oct 2026 | Sukhatme MayukhPresident & CIO | Tax withheld | 19,976 | 670K USD |
| 01 Oct 2026 | Epperly Melissa B,Director | Option exercise | 17,750 | 79K USD |
| 30 Sep 2026 | Gline MatthewCEO | Tax withheld | 76,171 | 2.8M USD |
| 30 Sep 2026 | Torti FrankPresident and Vant Chair | Tax withheld | 40,309 | 1.5M USD |
| 30 Sep 2026 | Venker EricPresident & Immunovant CEO | Option exercise | 200,000 | 770K USD |
| 30 Sep 2026 | Sukhatme MayukhPresident & CIO | Tax withheld | 46,879 | 1.7M USD |
Showing the 12 most recent of 35 compensation filings in this window. The figures above count all of them.
Which funds hold Roivant Sciences (ROIV)?
1 of the 45 institutional funds we track reported a Roivant Sciences position for the quarter ended 30 Sep 2026 — a combined 497K USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 13,597 | 497K USD | −14.5% |
Have members of Congress traded Roivant Sciences (ROIV)?
The most recent congressional trade disclosed in Roivant Sciences is a sale by Lisa C. McClain (house, MI), dated 31 Oct 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 31 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 21 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 22 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 22 days |
What has been filed or recorded for Roivant Sciences (ROIV)?
The filings we hold for Roivant Sciences, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 818 shares | 28K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,373 shares | 115K USD notional · <0.001% of shares out |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 719 shares | 26K USD notional · <0.001% of shares out |
| 25 Sep 2026 | Fails to deliver | Shares failed to deliver | 924 shares | 33K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.26 USD | Revenue $1M |
| 30 Jun 2026 | Financials | Total assets | 5.3B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 4.2B USD | at period end |
| 31 Mar 2026 | Annual report | FY 2025 reported | EPS −0.54 USD | Revenue $8M |
| 31 Mar 2026 | Financials | Revenue | 8.3M USD | fiscal year |
| 31 Mar 2026 | Financials | Net income | −299.8M USD | fiscal year |
| 31 Mar 2026 | Financials | Diluted EPS | −0.54 USD | fiscal year |
| 31 Dec 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.38 USD | Revenue $2M |
| 30 Sep 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.17 USD | Revenue $2M |
| 30 Jun 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.33 USD | Revenue $2M |
| 31 Mar 2025 | Annual report | FY 2024 reported | EPS −0.24 USD | Revenue $29M |
| 31 Dec 2024 | Quarterly earnings | Q3 2024 reported | EPS 0.23 USD | Revenue $9M |
| 30 Sep 2024 | Quarterly earnings | Q2 2024 reported | EPS −0.31 USD | Revenue $4M |
Roivant Sciences (ROIV): frequently asked questions
What did Roivant Sciences shares close at?
Roivant Sciences closed at 40.82 USD on 11 Sep 2026, down 0.31% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Roivant Sciences’ market cap?
Roivant Sciences is worth 29.5B USD by market value as of 11 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Roivant Sciences’ revenue?
Roivant Sciences reported revenue of 8.3M USD for the year ended 31 Mar 2026, as filed with the SEC. See Filings
Have Roivant Sciences insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Roivant Sciences insiders reported 15 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 20 Mar 2026, show no open-market purchase. A further 35 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Roivant Sciences?
1 of the 45 funds we track reported a Roivant Sciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Roivant Sciences?
Yes. 3 trades in Roivant Sciences appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 31 Oct 2025, filed 21 Nov 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Roivant Sciences last report earnings?
Roivant Sciences last reported earnings on 30 Jun 2026 for Q1 2026, with EPS of −0.26 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings